Search research articles
Contact Us
Filters
Showing results (51-60 of 209) with videos related to
Page
of 21
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 16, 2004
Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis
Robert J Fontana, Gregory T Everson, Sony Tuteja, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
November 16, 2007
The systemic safety of bromfenac ophthalmic solution 0.09%
Robert H Stewart, Lisa R Grillone, Mitchell L Shiffman, et al.
Journal of Clinical Microbiology
|
June 15, 2007
Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus
M Fernanda Sábato, Mitchell L Shiffman, Michael R Langley, et al.
Hepatology (Baltimore, Md.)
|
December 27, 2018
Financial Compensation For Hepatologists in Different Practice Settings
Mitchell L Shiffman, Norman L Sussman, Natarajan Ravendhran, et al.
Journal of Hepatology
|
April 14, 2010
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy
Christoph Sarrazin, Mitchell L Shiffman, Stephanos J Hadziyannis, et al.
Hepatology (Baltimore, Md.)
|
July 19, 2018
Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?
Mamta K Jain, Mae Thamer, George Therapondos, et al.
Plos One
|
March 19, 2016
A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
Tarik Asselah, Alex J Thompson, Robert Flisiak, et al.
Journal of Clinical and Experimental Hepatology
|
March 20, 2020
Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment
Robert J Wong, Mamta K Jain, George Therapondos, et al.
The American Journal of Gastroenterology
|
March 11, 2018
Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment
Robert J Wong, Mamta K Jain, George Therapondos, et al.
The American Journal of Gastroenterology
|
April 3, 2007
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy
John G McHutchison, Michael P Manns, Robert S Brown, et al.
Page
of 21
Search research articles
Search
Showing results (51-60 of 209) with videos related to
Sort By:
Page
of 21
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 16, 2004
Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis
Robert J Fontana, Gregory T Everson, Sony Tuteja, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
November 16, 2007
The systemic safety of bromfenac ophthalmic solution 0.09%
Robert H Stewart, Lisa R Grillone, Mitchell L Shiffman, et al.
Journal of Clinical Microbiology
|
June 15, 2007
Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus
M Fernanda Sábato, Mitchell L Shiffman, Michael R Langley, et al.
Hepatology (Baltimore, Md.)
|
December 27, 2018
Financial Compensation For Hepatologists in Different Practice Settings
Mitchell L Shiffman, Norman L Sussman, Natarajan Ravendhran, et al.
Journal of Hepatology
|
April 14, 2010
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy
Christoph Sarrazin, Mitchell L Shiffman, Stephanos J Hadziyannis, et al.
Hepatology (Baltimore, Md.)
|
July 19, 2018
Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?
Mamta K Jain, Mae Thamer, George Therapondos, et al.
Plos One
|
March 19, 2016
A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
Tarik Asselah, Alex J Thompson, Robert Flisiak, et al.
Journal of Clinical and Experimental Hepatology
|
March 20, 2020
Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment
Robert J Wong, Mamta K Jain, George Therapondos, et al.
The American Journal of Gastroenterology
|
March 11, 2018
Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment
Robert J Wong, Mamta K Jain, George Therapondos, et al.
The American Journal of Gastroenterology
|
April 3, 2007
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy
John G McHutchison, Michael P Manns, Robert S Brown, et al.
Page
of 21